Besides, Wang et al. revealed that SETD1A activates the Wnt/β-catenin pathway, which changes cancer stem cell characteristics as well as cisplatin sensitivity in NSCLC. This evidence concerns the gene SETD1A and non-small cell lung carcinoma.